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The neuronal Ca2+-sensor (NCS) proteins VILIP-1 and VILIP-3 have been implicated in
the etiology of Alzheimer’s disease (AD). Genome-wide association studies (GWAS) show
association of genetic variants of VILIP-1 (VSNL1) and VILIP-3 (HPCAL1) with AD+P
(+psychosis) and late onset AD (LOAD), respectively. In AD brains the expression of
VILIP-1 and VILIP-3 protein and mRNA is down-regulated in cortical and limbic areas. In
the hippocampus, for instance, reduced VILIP-1 mRNA levels correlate with the content
of neurofibrillary tangles (NFT) and amyloid plaques, the pathological characteristics of
AD, and with the mini mental state exam (MMSE), a test for cognitive impairment.
More recently, VILIP-1 was evaluated as a cerebrospinal fluid (CSF) biomarker and a
prognostic marker for cognitive decline in AD. In CSF increased VILIP-1 levels correlate
with levels of Aβ, tau, ApoE4, and reduced MMSE scores. These findings tie in
with previous results showing that VILIP-1 is involved in pathological mechanisms
of altered Ca2+-homeostasis leading to neuronal loss. In PC12 cells, depending on
co-expression with the neuroprotective Ca2+-buffer calbindin D28K, VILIP-1 enhanced
tau phosphorylation and cell death. On the other hand, VILIP-1 affects processes, such
as cyclic nucleotide signaling and dendritic growth, as well as nicotinergic modulation of
neuronal network activity, both of which regulate synaptic plasticity and cognition. Similar
to VILIP-1, its interaction partner α4β2 nicotinic acetylcholine receptor (nAChR) is severely
reduced in AD, causing severe cognitive deficits. Comparatively little is known about
VILIP-3, but its interaction with cytochrome b5, which is part of an antioxidative system
impaired in AD, hint toward a role in neuroprotection. A current hypothesis is that the
reduced expression of visinin-like protein (VSNLs) in AD is caused by selective vulnerability
of subpopulations of neurons, leading to the death of these VILIP-1-expressing neurons,
explaining its increased CSF levels. While the Ca2+-sensor appears to be a good biomarker
for the detrimental effects of Aβ in AD, its early, possibly Aβ-induced, down-regulation of
expression may additionally attenuate neuronal signal pathways regulating the functions
of dendrites and neuroplasticity, and as a consequence, this may contribute to cognitive
decline in early AD.
Keywords: cAMP/cGMP signaling, cognition, MAPK pathways, neurite outgrowth, neuroprotection, neuronal
Ca2+-sensors, nicotinic acetylcholine receptors, plasma membrane redox system
INTRODUCTION
In the old scriptures it is said: neither do men put new wine into
old bottles, else the bottles break, and the wine runneth out, and
the bottles perish, but they put new wine into new bottles, and
both are preserved (Matthew 9:17). In science the phrase “To put
old wine in new bottles” is often used when we aim to put old
knowledge in the context of new findings, in the hope to create a
good tasting wine. Recent findings on the implication of neuronal
Ca2+-sensor (NCS) proteins in the etiology of Alzheimer’s disease
(AD), particularly the role of VILIP-1 as cerebrospinal fluid (CSF)
biomarker for AD, its correlation with MMSE scores and predic-
tive value for cognitive decline in healthy individuals (Lee et al.,
2008; Craig-Schapiro et al., 2009; Tarawneh et al., 2011), provoke
new questions about what role these Ca2+-sensors play in early
cognitive impairment in AD. Some of our previous knowledge
about these proteins may help to find answers for these ques-
tions. Thus, in this review I will focus on two members of the
visinin-like protein (VSNL)-subfamily of NCS proteins, VILIP-1
and VILIP-3, reiterate some of the background information about
these Ca2+-signaling proteins, and summarize the current knowl-
edge about their effects on neuronal signaling, which may be of
potential relevance for the understanding of their link to disease
severity and early cognitive decline in AD.
THE VISININ-LIKE PROTEINS
Multiple Ca2+-sensing proteins have been identified in the cen-
tral nervous system (CNS) over the last decades, reflecting the
importance of the fine-tuning of the regulative function of
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Ca2+ in neurons. Several of these proteins have been grouped
together and termed NCS proteins (Nef, 1996; Braunewell and
Gundelfinger, 1999; Burgoyne and Weiss, 2001; Burgoyne, 2007).
Fourteen NCS protein genes related to the ubiquitous Ca2+-
sensor protein calmodulin exist in various species, and have been
subdivided into five subfamilies. VILIP-1 (visinin-like protein 1,
gene name VSNL1), VILIP-2 (visinin-like protein 2, gene name
hippocalcin-like 4, HPCAL4), VILIP-3 (visinin-like protein 3, gene
name HPCAL1), hippocalcin (gene name HPCA) and neurocal-
cin δ (gene name: NCALD) show amino acid identities between
67% and 94%, and form the subfamily of VSNLs (Braunewell
and Gundelfinger, 1999; Burgoyne and Weiss, 2001; Spilker et al.,
2002a; Burgoyne et al., 2004; Braunewell and Klein-Szanto, 2009).
Branch 1 of the VSNL subfamily consists of VILIP-1 and VILIP-2,
which are 89% homologous, and branch 2 consists of hippocal-
cin and VILIP-3, which share 94% identity, and both are 91%
identical to neurocalcin δ (Spilker et al., 2002a). VILIP-1 was first
cloned as visinin-like protein in chicken (Lenz et al., 1992), as
neural visinin-like protein 1 in rat (NVP-1) (Kuno et al., 1992),
as neurocalcin α from cow (Kato et al., 1998) and as VSNL1 in
man (Polymeropoulos et al., 1995). VILIP-3 orthologs are rem-
1 from chicken (Kraut et al., 1995), NVP-3 from rat (Kajimoto
et al., 1993) and hHLP2 from man (Kobayashi et al., 1994). The
protein sequences of VILIP-1 and VILIP-3 show 100% evolution-
ary conservation from chicken to man, indicating an important
functional role of these Ca2+-sensors in the CNS of various
species.
THE DISTRIBUTION OF VILIP-1 AND VILIP-3 IN THE CNS
VSNLs show a distinct but widespread expression pattern
with high expression levels in nerve cells (Braunewell and
Gundelfinger, 1999), but see Gierke et al. (2004) for an overview
on peripheral distribution of the proteins at lower levels. In the
periphery VILIP-1 has been implicated in cell migration and
is a putative tumor migration suppressor gene in several forms
of cancer (for review see Braunewell and Klein-Szanto, 2009).
A comprehensive mRNA expression study of the VSNL sub-
family describes the expression of VILIP-1, VILIP-2, VILIP-3
and hippocalcin in the rat brain (Paterlini et al., 2000). VILIP-
1 mRNA shows a widespread distribution in most brain areas
except the caudate-putamen. VILIP-3 exhibits strong expres-
sion in the cerebellum where it localizes to Purkinje and gran-
ule cells, and additional expression in the forebrain including
neocortex, hippocampus and caudate-putamen (Paterlini et al.,
2000). Comparative expression studies have been performed at
the protein level, including studies of VILIP-1 and VILIP-3 in
the rat cerebellum and hippocampus (Spilker et al., 2000), of
neurocalcin isoforms α (VILIP-1) and δ in the rat cerebellum
(Kato et al., 1998), and of VILIP-1 and VILIP-3 in the human
brain (Bernstein et al., 1999). Immunohistochemical studies
with VILIP-1-specific antibodies show expression in principal
and non-principal neurons. Particularly strong expression levels
are found in subpopulations of calbindin-D28K and calretinin-
positive GABAergic interneurons in all hippocampal regions
in the rat brain (Zhao and Braunewell, 2008). In hippocam-
pal interneurons VILIP-1 co-localizes mainly with the so-called
Ca2+-buffer proteins calbindin-D28K and calretinin (60–70%),
but much less pronounced with parvalbumin (<10%) (Bernstein
et al., 1999; Zhao and Braunewell, 2008). The rat expression pro-
file differs from the profile in the human hippocampus. VILIP-1
immunoreactive neurons were found in the hippocampal CA1,
CA4 and hilus regions, but were weak in the CA2 and CA3 areas
in the human brain (Bernstein et al., 1999). Strong VILIP-3 pro-
tein and mRNA expression has been localized in the cerebellum,
but expression in other brain regions including cortex and hip-
pocampus has been observed (Spilker et al., 2000; Hamashima
et al., 2001; Spilker and Braunewell, 2003). High expression levels
of VILIP-3 exist in the dentate gyrus at the mRNA level (Spilker
et al., 2000). VILIP-1 and VILIP-3 co-localize in hippocampal
neurons in culture, showing a strong expression for VILIP-1 in
many neurons and weaker expression of VILIP-3 in a subset of
neurons (Spilker and Braunewell, 2003). To further understand
the roles of these proteins in AD pathology, cellular and sub-
cellular co-localization studies of VSNLs with their interaction
partners need to be performed in AD brains and in AD animal
models in the future.
THE CA2+-MYRISTOYL SWITCH, TARGET INTERACTION,
AND NEURONAL CA2+-SIGNALING
VSNLs consist of 191–193 amino acid residues and harbor EF-
hands as Ca2+-binding motif. EF-hands consist of several core
amino acids involved in the coordinative binding of Ca2+ (D-X-
D/N-X-D/N-X-Y-(X)4-E). All VSNLs possess 4 EF-hands, how-
ever, EF-hand 1 is dysfunctional due to changes in the core amino
acid sequence (Braunewell, 2009; Braunewell and Klein-Szanto,
2009). At their N-terminus VSNLs bear a consensus sequence (M-
G-(X)3-S) for N-terminal myristoylation, which leads to the co-
translational attachment of a C14 myristic fatty acid. This modi-
fication enables all VSNLs to translocate to subcellular membrane
compartments (Kobayashi et al., 1993; Ladant, 1995; Lenz et al.,
1996; Spilker et al., 2002b) by a molecular mechanism termed
Ca2+-myristoyl switch (Zozulya and Stryer, 1992). The molecu-
lar mechanism of the switch has been first analyzed in detail from
tertiary structure data for the NCS protein recoverin. Binding of
Ca2+ to recoverin induces a conformational change leading to
surface exposure of hydrophobic protein parts and exposure of
the myristoyl side chain, thereby making these structures available
for interaction with cellular membranes and/or target proteins
(Tanaka et al., 1995; Ames et al., 1996, 1997). In living cells,
after increasing the intracellular Ca2+-concentration, VSNLs can
translocate to subcellular membrane compartments (Ivings et al.,
2002; Spilker et al., 2002b; O’Callaghan et al., 2002, 2003; Spilker
and Braunewell, 2003). However, the Ca2+-dependent subcellu-
lar membrane localization of endogenously expressed VILIP-1
and VILIP-3 differed substantially in the same hippocampal neu-
ron. VILIP-1 shows cell surface membrane association, including
membranes of axons and dendrites, which is in line with the
described function of VILIP-1 as modulator of cell surface associ-
ated proteins (Braunewell et al., 1997, 2001b; Lin et al., 2002a,b;
Chaumont et al., 2008; Richler et al., 2011). In addition, VILIP-1
only affiliates with trans-Golgi membranes following a Ca2+-
stimulus in hippocampal neurons (Spilker and Braunewell, 2003),
while VILIP-3 showed a weak Ca2+-independent Golgi local-
ization that was only gradually enhanced following stimulation
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of hippocampal neurons (Spilker et al., 2002b). Furthermore,
VILIP-3 interacts with intracellular juxtanuclear membranes and
granular structures in the whole cytosol (Spilker and Braunewell,
2003), which fits to a possible function as a modulator of MAP
kinases (Spilker et al., 2002a), and the ER-localized plasma mem-
brane redox system (PMRS) (Oikawa et al., 2004). Interestingly in
this context, under conditions of disturbed Ca2+-homeostasis in
AD an enhanced juxtanuclear membrane localization of VSNLs
exists (Braunewell et al., 2001a; Blandini et al., 2004). We will
need additional studies using markers for cellular organelles to
understand their distinct subcellular distribution pattern and the
re-distribution mechanisms following normal and pathological
Ca2+-signals.
The reversible localization of Ca2+-sensors to distinct mem-
brane compartments and signaling scaffolds in living neurons
has been postulated to be a signal transduction mechanism
for the selective activation of downstream signaling cascades,
such as receptors, receptor signaling complexes and signal effec-
tor molecules (Spilker et al., 2002b; Spilker and Braunewell,
2003). Besides EF-hand 1 as a putative functional domain for
VILIP-1 and VILIP-3, basic amino acids in the N-terminus
have been postulated to be involved in interaction with phos-
pholipids, particularly with their phosphatidylinositol phosphate
(PIP) headgroups. Unmyristoylated VILIP-1 can bind to artifi-
cial phospholipid bilayers in the absence of Ca2+, and monolayer
adsorption measurements showed a preference of binding to
PI(4,5)P2 over PI(3,4,5)P3 (Braunewell et al., 2010; Wang et al.,
2011). Furthermore, VILIP-1 and hippocalcin have been shown
to interact with PI(4,5)P2 at the cell surface membrane in hip-
pocampal neurons (O’Callaghan et al., 2005; Braunewell et al.,
2010). The functional implications of the additional phospholipid
interaction are not yet understood. EF-hand 1 forms the most
variable part in the sequence of NCS proteins and, therefore, com-
prises a possible interaction site with target proteins (Lian et al.,
2011). NCSs, such as VSNLs, serve as effectors to transduce cellu-
lar Ca2+-signals. Similar to the prototypical Ca2+-sensor calmod-
ulin, the VSNLs appear to be modulators of multiple intracellular
targets showing a “pleiotropy” of actions. VILIP-1 affects cAMP-
and cGMP signaling and downstream signaling pathways includ-
ing the rhoA/ROCK signaling pathway (Braunewell et al., 1997,
2001a; Mahloogi et al., 2003; Brackmann et al., 2005; Jheng et al.,
2006; Chen et al., 2009). It interacts with several ligand-gated
ion channels, such as glutamate receptors of the kainate subtype
GluR6 (Coussen et al., 2005), the P2X2 ATP receptor (Chaumont
et al., 2008), and the α4β2 nicotinic acetylcholine receptor
(nAChR) (Lin et al., 2002a). Interestingly, VILIP-1 forms dimers,
which appears to be important for the interaction with recep-
tor dimers/multimers, such as α4β2 nAChR and the natriuretic
peptide B receptor (NPR2, NPR-B) (Li et al., 2011; Wang et al.,
2011). Functionally, VILIP-1 enhances surface expression of NPR-
B, P2X2 ATP receptor and α4β2 nAChR (Brackmann et al., 2005;
Chaumont et al., 2008; Gierke et al., 2008). In contrast to VILIP-1,
comparatively little is known about signaling activities of VILIP-
3. Although it forms dimers with VILIP-1 (Jheng et al., 2006),
VILIP-3 does not affect the VILIP-1 target NPR-B (Spilker and
Braunewell, 2003; Chen et al., 2009). In contrast, VILIP-3 directly
or indirectly enhances activity of ERK1 and ERK2 (extracellular
signal-regulated kinase 1 and 2) MAPK (mitogen-activated
protein kinase) signaling (Spilker et al., 2002a), and inter-
acts with cytochrome b5, with unknown functional impact
(Oikawa et al., 2004).
NEURONAL CA2+-SIGNALING AND AD
According to the amyloid β (Aβ) hypothesis, excessive accu-
mulation of Aβ assemblies in the brain is involved in the eti-
ology of AD (Figure 1). Gradual accumulation of aggregated
Aβ initiates a complex, multistep cascade that includes inflam-
matory changes, gliosis, neuritic/synaptic changes, transmitter
loss, and formation of neurofibrillary tangles (NFT), leading
to cognitive impairments and ultimately to extensive cell death
in both sporadic (late-onset AD, LOAD: ApoE4 and other risk
factors) and familial or genetically linked AD (FAD with the
FIGURE 1 | The “neuronal Ca2+-sensor hypothesis” of Alzheimer’s
disease. In the Aβ hypothesis of AD genetic risk factors, such as mutations
in the amyloid precursor protein (APP) and the presenilins PS1 and PS2, but
also risks factors such as the apolipoprotein gene ApoeE4, age, nutrition or
exercise in sporadic AD lead to the excessive generation of toxic forms of
the Aβ peptide, which is derived from APP. Aβ then causes an impairment
of neuronal Ca2+-homeostasis resulting in the misregulation of neuronal
Ca2+-sensor (NCS) proteins. Pathological expression and function of NCS
proteins affects various neuronal signaling pathways involved in
neuroprotection, neuronal connectivity, and synaptic plasticity, which,
among other mechanisms, contribute to cognitive impairment and cell
death observed in AD.
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genetic risk factors APP—amyloid precursor protein, PS1 and
PS2—presenilins 1 and 2) (Hardy and Selkoe, 2002; Holtzman
et al., 2011). The molecular mechanisms involved are not com-
pletely understood. However, any AD hypothesis is challenged
to explain that the changes in synaptic physiology and the
onset of cognitive impairments long precede the massive cell
death that characterizes the later stages of AD. An extension
of the Aβ hypothesis to account for this fact, is the Ca2+-
hypothesis of AD. The hypothesis aims to explain how abnormal
Aβ metabolism induces a change in Ca2+-homeostasis, which
then initiates both, the early decline in memory and the later,
more massive changes in Ca2+-levels and the following increase
in neuronal cell death (for review see Foster, 2007; Bezprozvanny
and Mattson, 2008; Berridge, 2010; Supnet and Bezprozvanny,
2010; Chakroborty and Stutzmann, 2011). Aβ induces a mas-
sive disturbance of Ca2+-homeostasis by enhancing both, the
entry of external Ca2+ as well as the sensitivity of the InsP3 and
ryanodine receptors, that release Ca2+ from internal stores. Aβ
oligomers have been reported to increase Ca2+-influx by forming
Ca2+-pores in the plasma membrane and by regulating existing
plasma membrane Ca2+-channels. However, increased intracel-
lular Ca2+-levels are not only functionally linked to Aβ, but also
to presenilin mutations and ApoE4 expression. The initial local-
ized up-regulation of Ca2+-levels will then lead to re-modeling
of Ca2+-signaling pathways, such as for instance NCS signal-
ing (Figure 1), which leads to subtle effects on neurotransmis-
sion and synaptic plasticity underlying cognition (Chakroborty
and Stutzmann, 2011), and later to changes affecting mito-
chondrial (Supnet and Bezprozvanny, 2010) and endoplasmatic
reticulum Ca2+-pathways (Bezprozvanny and Mattson, 2008),
causing massive neuronal cell death. A current focus of the Ca2+-
hypothesis is to understand how the initial subtle dys-regulation
of Ca2+-signaling affects neuroplasticity and brings about the
early loss of memory. It also has been postulated that since the
defect in cognition occurs before there is any sign of massive
cell death, the development of drugs to normalize the subtle
changes in Ca2+-signaling may arrest the slow progression of AD
(Berridge, 2010).
THE ROLE OF NCS PROTEINS IN AD: NEUROPROTECTION
VERSUS NEUROTOXICITY
NCS proteins have been implicated in cognitive processes and
in the pathology of AD (for review see Blandini et al., 2004;
Buxbaum, 2004; Braunewell, 2005; Braunewell and Bernstein,
2009; Craig-Schapiro et al., 2009). There is less protein expres-
sion of VILIP-1, and the numbers of VILIP-1- and, to a lesser
degree, VILIP-3-immunoreactive neurons are reduced in the tem-
poral cortex of AD patients, (Bernstein et al., 1999). These data
point to a disease-related loss of VSNLs. In AD brains, extracel-
lularly located VSNLs are in close association with the pathologic
lesions, such as dystrophic nerve cell processes, amorphous and
neuritic plaques, and extracellular NFTs, indicating that they may
be involved in the pathophysiology of altered Ca2+-homeostasis
in AD (Braunewell et al., 2001a). In PC12 pheochromocytoma
cells, VILIP-1 over-expression enhances hyper-phosphorylation
of tau protein, which destabilizes microtubules, and, in trans-
fected PC12 cells, it increases Ca2+-mediated cell death (Schnurra
et al., 2001). Co-expression of the Ca2+-buffer protein, calbindin-
D28K, which is neuroprotective and down-regulated in AD
(Iacopino and Christakos, 1992; McMahon et al., 1998), atten-
uates the effect of VILIP-1 on cell death induced by ionomycin.
In this context, VILIP-1 has a widespread distribution in the
brain, including in GABAergic neurons (Bernstein et al., 1999).
In addition to being expressed in most pyramidal neurons of
human and rat hippocampi, it largely co-localizes with calbindin-
D28K and calretinin in GABAergic interneurons (Zhao and
Braunewell, 2008), but less with parvalbumin-positive interneu-
rons. In interneurons of transgenic AD mouse models and in AD
brains, the Ca2+-buffer proteins, calbindin-D28K and calretinin,
are down-regulated (Kaufmann et al., 1998; Palop et al., 2003,
2007; Popovic´ et al., 2008; Baglietto-Vargas et al., 2010; Takahashi
et al., 2010). These findings suggest that the ratio of expression of
Ca2+-sensor to Ca2+-buffer proteins may define subpopulations
of neurons particularly vulnerable to Aβ-induced and Ca2+-
mediated neurotoxicity (Figure 2). Since interneurons are essen-
tial for the generation of synchronous rhythmic activity in the
hippocampus, which is underlying cognitive processing/memory
encoding, the early alterations of hippocampal inhibitory func-
tionality in AD may result in the cognitive impairments seen in
the initial stages of the disease (Palop and Mucke, 2010). On
FIGURE 2 | Neuroprotective versus neurotoxic role of Ca2+-binding
proteins in the pathology of AD. Aβ deposition is believed to cause
changes in the Ca2+-homeostasis that lead to pathological expression and
activation of NCS proteins, such as calsenilin and VILIP-1. Calsenilin, which
is up-regulated in AD, promotes apoptotic cell death in a manner dependent
on presenilin-2 (PS2), but has been found to be neuroprotective in PC12
cells. In contrast, VILIP-1 is down-regulated in AD. Over-expression of
VILIP-1 leads to tau phosphorylation and cell death in PC12 neurons, which
is attenuated by expression of the Ca2+-buffer protein calbindin-D28K.
Thus, in AD brains, an imbalance in the ratio of Ca2+-sensor (Calsenilin,
VILIP-1) versus Ca2+-buffer proteins (CB/CR: calbindin-D28K, calretinin) in
subpopulations of neurons may lead to their selective vulnerability and early
loss, and, in turn, to the appearance of extracellular VSNLs, which are
associated with the pathologic hallmarks amyloid plaques and
neurofibrillary tangles (NFT). VILIP-1 is detected in the cerebrospinal fluid
(CSF) of AD patients, and serves as a CSF biomarker. Increased levels
correlate with CSF t-tau, p-tau, the ApoE ε4/ε4 genotype, and with mini
mental state examination (MMSE) scores of AD patients.
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the other hand, for the related VSNL hippocalcin a neuropro-
tective role has been postulated in age-related neurodegeneration
(Masuo et al., 2007). The only other NCS protein that has been
implicated in AD (Figure 2) and which is not belonging to the
VILIP subfamily, is Calsenilin/DREAM/KChIP3. It was indepen-
dently identified as a NCS protein that interacts with presenilins
(PS1 and 2), serves as a transcription repressor, and binds to
A-type potassium channels (Buxbaum et al., 1998; Carrión et al.,
1999; An et al., 2000). Calsenilin levels are elevated in the cortex
region of AD brains and in the neocortex and the hippocam-
pus of brains of Swedish mutant beta-amyloid precursor protein
(sweAPP) transgenic mice. When cultured cortical and hip-
pocampal neurons are exposed to Aβ this induces both calsenilin
protein and mRNA expression, and cell death, whereas calsenilin
expression blockade protects against Aβ toxicity (Jo et al., 2004).
In contrast, in Xenopus oocytes calsenilin reversed the pathogenic
effects of mutant PS1 on Ins(1,4,5)P3-mediated Ca2+-signaling.
Presenilin mutations perturb intracellular Ca2+-signaling path-
ways contributing to the key features of AD, such as increased
Aβ production, tau hyper-phosphorylation, and enhanced vul-
nerability to cell death. Calsenilin expression reversed the mutant
PS-1-enhanced amplitudes and altered kinetics of Ca2+-signals in
oocytes (Leissring et al., 2000). Rivas et al. found recently, using
the yeast two-hybrid assay, that DREAM interacts with perox-
iredoxin 3 (Prdx3), an antioxidant enzyme found in mitochon-
dria (Rivas et al., 2011). The peroxiredoxin system is a cellular
defense system against oxidative stress, and the decreased protein
levels of Prdx3 in AD has been discussed as the results of mito-
chondrial damage, which may reduce cellular protection against
oxidative damage (Kim et al., 2001). The Prdx3-DREAM inter-
action modulates the DREAM redox state and in turn modulates
transcriptional repression by DREAM. Since transient DREAM
knockdown in PC12 cells sensitizes these cells to H(2)O(2)-
induced oxidative stress, this would suggest a protective role
for DREAM against oxidative damage (Rivas et al., 2011). In
the future the careful re-evaluation of the potential neurotoxic
versus neuroprotective roles of NCS proteins in AD-related cel-
lular models and in AD animal models is necessary to define
whether different NCS proteins show neurotoxic and/or neuro-
protective properties under the specific conditions of disturbed
Ca2+-homeostasis in AD brains.
VSNLs AS BIOMARKERS FOR AD—OLD WINE IN NEW
BOTTLES
Association of VSNLs with the pathologic hallmarks of AD have
been published more than a decade ago. More recent support
for a functional role of VSNLs in AD comes from genome-
wide association studies (GWAS). An SNP for VILIP-1 associates
(rs4038131, p = 5.9× 10−7) with AD and subsequent psychosis
(Hollingworth et al., 2011). For VILIP-3, there was an associ-
ation of 2 SNPs (rs1019785, rs10197851, p = 3.67× 10−6, p =
7.13× 10−6) with LOAD; this was replicated in the NIH LOAD
data set (Lee et al., 2011). VILIP-1 seems to have additional roles
in the cognitive impairments associated with AD. The early find-
ings of reduced protein expression of VSNLs (Bernstein et al.,
1999; Schnurra et al., 2001) have been confirmed for brain areas
other than the temporal cortex, and extended to changes in
mRNA levels. For example, in postmortem brains of AD patients,
there is lower expression of VILIP-1 mRNA in the amygdala,
cingulate cortex, hippocampus, and cerebellum (Loring et al.,
2001; Youn et al., 2007). Whole-genome expression profiling of
RNA obtained from the frontal cortex identified genes associ-
ated with cognitive decline, and expression of VILIP-1 mRNA
correlated with NFT content and with the MMSE scores of AD
patients (Wilmot et al., 2008). Similarly, two independent re-
analyses were performed on a microarray dataset corresponding
to hippocampus gene expression for AD subjects with varying
degrees of severity (contributed by Blalock et al., 2004), found
down-regulation of VILIP-1 mRNA, association with NFT con-
tent in the hippocampus, and again an association with the
MMSE score (Miller et al., 2008; Gómez Ravetti et al., 2010).
These data indicate that VILIP-1 expression is lost not only due
to loss of VILIP-1-expressing neurons (Bernstein et al., 1999;
Schnurra et al., 2001), but also to pathological down-regulation
of VILIP-1 mRNA levels. The lowered VILIP-1 mRNA expression
correlated with the severity of cognitive decline, as measured by
MMSE scores for AD subjects. Similarly, an observation by Lee
et al., 2008 ties in with these results on VILIP-1-MMSE corre-
lation in microarray studies (Miller et al., 2008; Gómez Ravetti
et al., 2010). In this study, CSF samples were analyzed by ELISA
to measure concentrations of Aβ1–42, t-tau, p-tau, and VILIP-1.
However, in contrast to VILIP-1 mRNA signals, in the CSF of AD
subjects, VILIP-1 protein is increased, relative to controls. There
was also strong correlation of increased CSF-VILIP-1 with CSF
t-tau, p-tau, the ApoE ε4/ε4 genotype, and lowered MMSE scores
of AD patients (Lee et al., 2008). The new findings of the appear-
ance of the intracellular protein VILIP-1 in the CSF is consistent
with the older view that VILIP-1 is released from neurons during
neurotoxic insults, and that extracellular VILIP-1 then associates
with the pathologic characteristics of AD (Schnurra et al., 2001;
Braunewell et al., 2001a). Thus, although VILIP-1mRNA appears
to be actively down-regulated in AD and the down-regulation
correlates with reduced MMSE scores, at the same time neurons
expressing VILIP-1 seem to be particularly vulnerable against Aβ-
induced disturbances of Ca2+-homeostasis, and these neurons
appear to die early on in the disease. This would explain how
the intracellular protein is released from neurons and can then
be found associated with amyloid plaques and NFT, and finally
makes its way into the CSF. Thus, there appears to be signifi-
cant correlation of reduced VILIP-1 mRNA as well as enhanced
CSF protein levels with reduced MMSE scores and early cognitive
decline in AD.
VILIP-1 AND COGNITIVE IMPAIRMENT IN AD?
Since VILIP-1 concentrations in the CSF correlate with MMSE
scores, CSF-VILIP-1 has been proposed as a marker for declined
cognition and disease severity (Verbeek and Olde Rikkert, 2008;
Craig-Schapiro et al., 2009). This assumption from the Lee et al.,
2008 study prompted a larger study in 300 subjects, where VILIP-
1 was confirmed as a CSF biomarker for early AD (Tarawneh
et al., 2011). In this study VILIP-1 also showed elevated plasma
levels. Importantly, the Holtzman group also describes a 2–3 year
follow-up study in cognitively healthy control subjects, in which
CSF levels of VILIP-1 in still healthy individuals had predictive
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value for future cognitive decline (Tarawneh et al., 2011). Thus,
the correlation of CSF VILIP-1 with MMSE scores suggests that
VILIP-1 in the CSF is a valid biomarker, and is a prognostic
marker for cognitive decline in early AD (Craig-Schapiro et al.,
2009; Tarawneh et al., 2011). Notably, in non-AD dementias no
increased VILIP-1 CSF levels were detected, pointing to the possi-
bility that VILIP-1 may be linked to disease-specific mechanisms
or alterations in signaling pathways (Tarawneh et al., 2011). These
novel observations should raise a variety of new research ques-
tions. More support that VILIP-1 is directly associated with cog-
nitive capabilities comes from a study showing that VSNL1 SNPs
are associated with performance in the Wisconsin Card Sorting
Test, an assessment of frontal cortical function in schizophrenia
patients with cognitive impairments (Braunewell et al., 2011).
These results also raise the question of whether VILIP-1, in addi-
tion to its role in Aβ-induced and Ca2+-mediated neuronal death,
might be involved in neuronal signaling pathways and mecha-
nisms of impaired synaptic plasticity and cognition in AD. Other
related NCS proteins, including Calsenilin/DREAM/KChIP3 and
NCS-1, affect synaptic plasticity (Sippy et al., 2003; Fontán-
Lozano et al., 2009; Saab et al., 2009; Wu et al., 2010). VSNLs
are specialized mediators of Ca2+-signals in neuronal signal-
ing processes known to affect cognition. VILIP-2 was shown
to slow inactivation of Ca(V)2.1 channels in a myristoylation
dependent manner (Few et al., 2005). Ca(V)2.1 channels con-
duct P/Q-type Ca2+-currents, and initiate synaptic transmission
at most synapses in the CNS. The VILIP-2-dependent facilita-
tion and inactivation of these channels contributes to short-term
synaptic plasticity (Nanou et al., 2012). Hippocalcin acts as Ca2+-
sensor for hippocampal long-term depression (Palmer et al.,
2005), and hippocalcin knockout animals display impaired spa-
tial and associative memory (Kobayashi et al., 2005). Moreover,
it was shown show that expression of hippocalcin, but not of a
hippocalcin myristoylation mutant, leads to an enhanced slow
afterhyperpolarization current I(sAHP) in cultured hippocam-
pal neurons. A train of action potentials activates potassium
channels in a Ca2+-dependent manner to produce the sAHP
current, which in turns dampens neuronal excitability. This was
strongly reduced in hippocalcin knockout animals (Tzingounis
et al., 2007). The modulation of sAHP currents is believed to reg-
ulate neuronal excitability, synaptic efficacy, and the threshold for
tetanus-induced synaptic plasticity. Hippocalcin and neurocalcin
δ, but not VILIP-2, can also act as a Ca2+-sensor for the sAHP cur-
rent in the cerebral cortex, indicating that VSNLs can gate sAHPs
and thus neuronal excitability in various brain regions (Villalobos
and Andrade, 2010). It is likely that VILIP-1 and -3 have similar
functions in regulating neuronal excitability and synaptic plas-
ticity, particularly since VILIP-1 up-regulation has been linked
to mGluR-dependent long-term potentiation (Braunewell et al.,
2003; Brackmann et al., 2004).
VILIP-1, DENDRITIC CONNECTIVITY AND COGNITIVE
IMPAIRMENT IN AD
A major question is how VILIP-1 and VILIP-3 may influ-
ence cognition. One possibility for VILIP-1 is that it activates
cyclic AMP- and cyclic GMP-signaling by enhancing surface
expression of membrane-localized adenylyl and guanylyl cyclases
(Brackmann et al., 2005; Braunewell et al., 2011). Thereby,
VILIP-1 might influence cAMP and cGMP-dependent neuronal
processes, including neuronal differentiation, neurite outgrowth,
different forms of synaptic plasticity and learning and mem-
ory (Schuman and Madison, 1991; Telegdy, 1994; Monfort
et al., 2002). The regulation of cAMP-levels by VILIP-1 has
been initially detected in stably transfected rat C6 glioma cells
(Braunewell et al., 1997). The myristoylation-deficient mutant
of VILIP-1, which lacks the myristoylation consensus motif and,
therefore, does not exhibit the Ca2+-myristoyl switch, showed
a dominant-negative effect on cAMP-levels in C6 cells. Already
basic cAMP levels appeared to be elevated in VILIP-1-transfected
C6 cells, which is the cause for induction of differentiation of
those glioma cells (Braunewell and Gundelfinger, 1997). VILIP-
1 appears to influence adenylyl cyclase activity in selected cell
types including human embryonic kidney cells (Lin et al., 2002b),
the pancreatic β cell line MIN6 (Dai et al., 2006), and var-
ious skin tumor cell lines, where it also affects rhoA signal-
ing (Mahloogi et al., 2003; Schönrath et al., 2011). No direct
interaction of VILIP-1 with adenylyl cyclase isoforms has been
detected, but VILIP-1 expression was shown to enhance sur-
face expression of different adenylyl cyclase isoforms in skin
tumor cell lines leading to enhanced tumor cell migration
(Schönrath et al., 2011).
VILIP-1 enhances neurite outgrowth in SH-SY5Y neuroblas-
toma via effects on cAMP-signaling (Braunewell et al., 2011).
The cAMP signaling pathway overcomes Aβ-induced inhibition
of neurite formation in SH-SY5Y neurons and in the hippocam-
pus in transgenic APP/PS1 mice, carrying human AD muta-
tions (Smith et al., 2009). In SH-SY5Y cells, Aβ reduces cAMP
levels and increases levels of the GTP-bound (active) form of
rhoA, which is eliminated by the rho-associated protein kinase
(ROCK) inhibitor, Y-27632 (Petratos et al., 2008). Manipulation
of the cAMP-rhoA/ROCK signaling pathway using the ROCK
inhibitor leads to the extension of long neurites in SH-SY5Y
cells. Consistent with the effect of VILIP-1 on cAMP signaling in
SH-SY5Y neurons, the reduction of its expression through expo-
sure of cells to siRNA results in loss of dendritic arborisation as
measured as reduced number of dendrites in a Sholl analysis in
hippocampal neurons. This effect is likely due to the observed
reduced VILIP-1-dependent formation of cAMP in hippocam-
pal neurons. As expected over-expression of VILIP-1 led to an
increase in the number of dendrites in these neurons (Braunewell
et al., 2011). It is noteworthy that calbindin-D28K, the neuropro-
tective Ca2+-buffer protein which is down-regulated in AD and
co-localizes with VILIP-1 in hippocampal interneurons (Gierke
et al., 2008; Zhao and Braunewell, 2008), promotes neuronal
differentiation and neurite outgrowth of hippocampal precursor
cells and dopaminergic neurons (Choi et al., 2001; Kim et al.,
2006). Similarly, hippocalcin enhances basic fibroblast growth
factor-induced neurite outgrowth in a hippocampal cell line (Oh
et al., 2008). Interestingly in another study, VILIP-1 and neuro-
calcin δ were found to be developmentally up-regulated in axon
tracts in the olfactory system. Counter-intuitively, their over-
expression led to reduced axon outgrowth, but left dendrite length
unaffected in hippocampal neurons in the same study (Yamatani
et al., 2010). Whereas neurocalcin δ also showed reduced branch
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point and dendrite numbers, VILIP-1 appeared to only slightly
increase dendrite numbers, although not significantly (Yamatani
et al., 2010). It is highly likely that different VSNLs may affect
different neuronal compartments, with VILIP-1 reducing axonal
(Yamatani et al., 2010), but enhancing dendritic differentiation
(Braunewell et al., 2011). However, comparative studies on axonal
versus dendritic differentiation will have to be performed in the
same experimental set up to further substantiate this hypothesis.
Particularly the effect of VILIP-1 and, possibly, VILIP-3 on den-
dritic arborization and connectivity may underlie altered synaptic
function and hippocampal network connectivity, and thus may
contribute to the cognitive decline in early phases of AD. The
loss of distinct Ca2+-buffer and Ca2+-sensor proteins in subpop-
ulations of hippocampal interneurons, may render these neurons
particularly vulnerable against Aβ-inducedmorphological distur-
bances, such as reduced dendritic spinogenesis in AD, which are
significantly contributing to cognitive decline (Smith et al., 2009;
Wei et al., 2010).
VILIP-1, NICOTINERGIC SIGNALING AND COGNITIVE
IMPAIRMENT IN AD
One other possibility how VILIP-1 may affect cognition lies
in the fact that VILIP-1 interacts with the α4β2 nAChR (Lin
et al., 2002a). Reduced levels of nAChRs and cholinergic neu-
rotransmission are involved in the etiology of AD, and acetyl-
cholinesterase inhibitors are used for the treatment of AD
(Buckingham et al., 2009). The high-affinity α4β2 nAChR is
the main nicotine binding site in the brain, and appears to
mediate nicotine-dependent improvements in attention, learn-
ing, and working memory (Rezvani and Levin, 2001; Levin
et al., 2006). These facts have sparked interest in the devel-
opment of novel treatments for cognitive dysfunction in CNS
disorders, based on modulation of nAChR activity. In clini-
cal trials, agonists and antagonists of the major α7- and α4-
containing nAChRs are beneficial (Buckingham et al., 2009;
Bacher et al., 2009; Fedorov et al., 2009). Since VILIP-1 is an
endogenous modulator of α4β2 nAChR, it is conceivable that
the down-regulation of VILIP-1 mRNA at early stages of AD
leads to deficits in α4β2 nAChR activity in the hippocampus.
In a yeast two-hybrid screen for protein-protein interactions,
VILIP-1 bound to a 30-amino acid region in the large intracel-
lular loop of the α4 -subunit of the α4β2 nAChR. Co-expression
of VILIP-1 with recombinant α4β2 nAChR up-regulated the
surface expression levels by twofold and increased the agonist-
sensitivity to acetylcholine by threefold. The VILIP-1 myristoy-
lation mutant or mutants not able to bind Ca2+ are found to
attenuate the modulation of α4β2 nAChR (Lin et al., 2002a).
Similarly, in hippocampal neurons, co-expression of VILIP-1with
recombinant α4β2 nAChR up-regulated its surface expression
and increased the agonist sensitivity to acetylcholine, suggest-
ing that VILIP-1 is a modulator of α4β2 nAChR, and lead-
ing to functional up-regulation of the receptor (Zhao et al.,
2009a). VILIP-1 and α4β2 nAChR were found in a complex with
the trans-Golgi SNARE syntaxin 6, involved in Golgi to sur-
face membrane trafficking and constitutive exocytosis. Moreover,
the nicotine-induced, and α7 nAChR-mediated Ca2+-myristoyl
switch of VILIP-1 in hippocampal neurons provides a crosstalk
mechanism for the interaction of α7 with α4β2 nAChRs, in
that the α7 nAChR mediated Ca2+-influx in neurons can acti-
vate α4β2 nAChRs via VILIP-1 (Zhao et al., 2009b Figure 3).
In rat and human hippocampi, VILIP-1 and α4β2 nAChR are
co-localized in a subpopulation of interneurons (Gierke et al.,
2008; Zhao and Braunewell, 2008). In view of the prominent
expression of VILIP-1 in calbindin-positive interneurons and in
disinhibitory, calretinin-positive interneurons in the hippocam-
pal formation, which are also partly positive for α4β2 nAChR
(Zhao and Braunewell, 2008), VILIP-1 is well positioned to reg-
ulate hippocampal network activity. The interaction of VILIP-1
with α4β2 nAChR enhances GABAergic signaling in interneu-
rons, and the frequency of IPSCs (inhibitory postsynaptic cur-
rents) in pyramidal neurons (Gierke et al., 2008), thereby likely
changing the activity of the hippocampal neuronal network, and
thus synaptic plasticity and cognition (Rezvani and Levin, 2001;
Levin et al., 2006). Interneurons are involved in the generation
of synchronous rhythmic activity in the hippocampus essential
for cognitive processing/memory encoding. Therefore, early alter-
ations in hippocampal interneurons in AD may result in the
cognitive impairments seen in the initial stages of the disease
(Palop et al., 2003, 2007; Baglietto-Vargas et al., 2010). In AD
the loss of VILIP-1 expression may thus lead to a loss of surface
expression and functional activity of α4β2 nAChRs in interneu-
rons, and in turn reduction of GABAergic interneuron activity
(Figure 3). The effect of VILIP-1 on nicotinergic signaling, in
hippocampal interneurons, for instance, may explain the cor-
relation of CSF VILIP-1 levels and VILIP-1 mRNA levels with
MMSE scores and cognition. Thus, down-regulation of VILIP-1
FIGURE 3 | Molecular mechanisms of the involvement of VILIP-1 in
pathological network activity and cognition. (1) The amyloid β peptide
binds to and activates receptors, such as the α7 nAChR and NMDA-type
glutamate receptors, leading to changes in the cellular Ca2+-homeostasis.
The increase in Ca2+ concentrations shuttles VILIP-1 to the cell surface and
Golgi membranes. (2) VILIP-1 enhances surface expression and sensitivity
of α4β2 nAChRs in interneurons. (3) In hippocampal interneurons VILIP-1
enhances up-regulation of α4β2 nAChRs and thereby modulates GABA
release. This leads to a VILIP-1-dependent enhancement of ACh-evoked
IPSCs in hippocampal pyramidal cells. The pathological down-regulation of
VILIP-1 in AD may thus negatively affect hippocampal network activity and
synaptic plasticity, and lead to cognitive disturbances in the AD brain.
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affecting α4β2 nAChR expression and activity in interneurons
may contribute to cognitive impairments in AD.
VILIP-3 AND THE PLASMA MEMBRANE REDOX
SYSTEM IN AD
Comparatively little is known about functional activities of
VILIP-3. VILIP-3 affects ERK1/2-phosphorylation in PC12 cells
(Spilker et al., 2002a), has been discussed to enhance cAMP
levels in the prostatic epithelial cell line NbE-1 (Tang et al.,
2012), and VILIP-3 as well as hippocalcin, interact with the
microsomal enzyme cytochrome b5, which in turn interacts with
cytochrome b5 reductase located in the endoplasmic reticulum-
perinuclear region in microsomal membranes (Oikawa et al.,
2004). Cytochrome b5 belongs to the PMRS (Hyun et al., 2006).
Membrane-associated oxidative stress has been implicated in the
synaptic dysfunction and neuronal degeneration that occurs in
AD, but the underlying mechanisms are unknown. The PMRS
provides electrons for energy metabolism and recycling of antiox-
idants, and is impaired in AD (Hyun et al., 2010). The activities
of several PMRS enzymes are decreased in plasma membranes
from the hippocampus and cerebral cortex of 3xTgAD mice,
an animal model of AD. Neurons over-expressing the PMRS
enzymes (NQO1 or cytochrome b5 reductase) exhibit increased
resistance to Aβ (Hyun et al., 2010). Under conditions of dis-
turbed Ca2+-homeostasis in AD, there is an enhanced patho-
logical, juxtanuclear localization of VILIP-3 (Braunewell et al.,
2001a). The Ca2+-dependent translocation of VILIP-3 to the
endoplasmic reticulum (ER)-rich perinuclear region, may indi-
cate that VILIP-3 impacts the microsomal monooxygenase com-
plex composed of cytchrome b5-reductase, cytochrome P450, and
other reductases of the ER. Although the functional implica-
tions of the interaction are not yet known, reduced expression
of VILIP-3 may decrease PMSR activity and lead to enhanced
oxidative stress. Thus, increased levels of VILIP-3 may be neu-
roprotective against Aβ-induced oxidative stress. In this context,
hippocalcin also appears to be neuroprotective (Mercer et al.,
2000; Lindholm et al., 2002). Hippocalcin−/− mice are more
sensitive to thapsigargin-induced cell death and to excitotoxic-
ity caused by kainic acid and quinolinic acid (Korhonen et al.,
2005; Masuo et al., 2007). Moreover, these mice display increased
caspase-12 activation and an age-dependent increase in neurode-
generation (Masuo et al., 2007). Interestingly, DREAM, which
is upregulated in AD (Jo et al., 2004), was found to inter-
act with the mitochondrial antioxidant enzyme Prdx3 (Rivas
et al., 2011). Prdx3 expression protected against pesticide-induced
mitochondrial damage, it improved cognition and decreased
Aβ levels in APP transgenic mice (Chen et al., 2012). DREAM
knockdown sensitizes H(2)O(2)-induced oxidative stress in PC12
cells, thus DREAM up-regulation has been discussed to be
neuroprotective against oxidative stress (Rivas et al., 2011). It
will be interesting to investigate whether there is actually co-
localization of DREAM with Prdx3 in mitochondria or in the
cytosol, and whether this interaction leads to neuroprotection
under pathological conditions in an AD model. Taken together,
these results indicate that plasma membrane, ER and mito-
chondrial redox systems play a crucial role in both oxidative
stress-induced cell death and in cognitive impairment in AD,
and it will be important to clarify whether the observed inter-
actions of NCS proteins with different components of redox
systems may affect the functionality of antioxidant systems in
AD, and vice versa. These interactions may underlie some of
the neurotoxic/neuroprotective and cognitive functions of NCS
proteins in AD.
FUTURE PERSPECTIVES
There are many open questions concerning the role of Ca2+-
signaling and particularly the role of Ca2+-sensors, such as
Calsenilin and VSNLs, in the etiology of AD. The complex pat-
tern of up- and down-regulation of NCSs, and of Ca2+-buffers,
such as calbindin-D28K and calretinin, may have multiple addi-
tive effects on neuronal pathways and systems at various levels
and intensities, and thereby significantly contribute to cognitive
impairments in AD and to neuronal death at the later stages
of AD. In order to determine the effects of VSNLs, in conjunc-
tion with their respective interaction partners and associated
signaling pathways, and to determine whether they are thera-
peutic targets for treatment of cognitive impairments in AD,
several important questions need to be answered in the future
(Working hypothesis Figure 4). First, (1) what are the mech-
anisms of VILIP down-regulation in AD. One possibility is a
direct down-regulation by Aβ, or alternatively via Aβ-supression
of neurotrophin signaling. Next, (2) what is the role VSNLs
play in Aβ-induced Ca2+-overload, leading to reduced activity of
the PMRS and to impaired neuroprotection in vulnerable sub-
populations of neurons. (3) What are the signaling pathways
involved in the effect of VILIP-1 on tau-phosphorylation and
(4) on dendritic growth and spinogenesis in neurons? Finally,
whether there is changed expression of VSNLs, particularly in
FIGURE 4 | Future perspectives. Working hypothesis and open questions
on the involvement of VSNLs and associated signaling pathways as
mediators of Aβ oligomer-induced cell death and detrimental effects on
cognition in AD.
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interneurons, that affects network activity and synaptic plasticity
in transgenic AD animal models, and most importantly
(5) whether for instance VILIP-1, via its modulatory effect
on cAMP and nicotinergic signaling plays a role for impaired
synaptic plasticity and cognition in animal models. Such an effect
could contribute to some of the early cognitive impairments
observed in AD.
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